PUBLICATION
Repeated microdoses of LSD do not alter anxiety or boldness in zebrafish
- Authors
- Hagen, E.V., Schalomon, M., Zhang, Y., Hamilton, T.J.
- ID
- ZDB-PUB-240223-11
- Date
- 2024
- Source
- Scientific Reports 14: 43894389 (Journal)
- Registered Authors
- Hamilton, Trevor
- Keywords
- none
- MeSH Terms
-
- Animals
- Anxiety
- Hallucinogens*/pharmacology
- Locomotion
- Lysergic Acid Diethylamide*/pharmacology
- Models, Animal
- Zebrafish
- PubMed
- 38388550 Full text @ Sci. Rep.
Citation
Hagen, E.V., Schalomon, M., Zhang, Y., Hamilton, T.J. (2024) Repeated microdoses of LSD do not alter anxiety or boldness in zebrafish. Scientific Reports. 14:43894389.
Abstract
The therapeutic use of lysergic acid diethylamide (LSD) has resurfaced in the last decade, prompting further scientific investigation into its effectiveness in many animal models. Zebrafish (Danio rerio) are a popular model organism in medical sciences and are used to examine the repeated administration of pharmacological compounds. Previous zebrafish research found acute LSD altered behaviour and cortisol levels at high (250 µg/L) but not low (5-100 µg/L) levels. In this study, we used a motion tracking system to record and analyze the movement patterns of zebrafish after acute and repeated 10-day LSD exposure (1.5 µg/L, 15 µg/L, 150 µg/L) and after seven days of withdrawal. The open-field and novel object approach tests were used to examine anxiety-like behaviour, boldness, and locomotion. In the acute experiments we observed a significant decrease in high mobility with 1.5 µg/L, 15 µg/L, and 150 µg/L of LSD compared to the control and a decrease in velocity with 1.5 and 15 µg/L. In repeated experiments, there were no significant differences in the levels of anxiety, boldness, or locomotion between all LSD groups and controls immediately after 10-day treatment or after withdrawal.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping